472 related articles for article (PubMed ID: 33131912)
1. Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States.
Talan DA; Takhar SS; Krishnadasan A; Mower WR; Pallin DJ; Garg M; Femling J; Rothman RE; Moore JC; Jones AE; Lovecchio F; Jui J; Steele MT; Stubbs AM; Chiang WK; Moran GJ
Ann Emerg Med; 2021 Jan; 77(1):32-43. PubMed ID: 33131912
[TBL] [Abstract][Full Text] [Related]
2. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
3. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.
García-Tello A; Gimbernat H; Redondo C; Meilán E; Arana DM; Cacho J; Dorado JF; Angulo JC
Scand J Urol; 2018 Feb; 52(1):70-75. PubMed ID: 28893132
[TBL] [Abstract][Full Text] [Related]
4. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
5. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
6. A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection.
Liu H; Qiu S; Chen M; Lyu J; Yu G; Xue L
BMC Infect Dis; 2022 Jan; 22(1):50. PubMed ID: 35027010
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
Vardi M; Kochavi T; Denekamp Y; Bitterman H
Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
[TBL] [Abstract][Full Text] [Related]
8. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
9. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
11. Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance.
Niehus R; van Kleef E; Mo Y; Turlej-Rogacka A; Lammens C; Carmeli Y; Goossens H; Tacconelli E; Carevic B; Preotescu L; Malhotra-Kumar S; Cooper BS
Elife; 2020 May; 9():. PubMed ID: 32379042
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population.
Eltai NO; Al Thani AA; Al-Ansari K; Deshmukh AS; Wehedy E; Al-Hadidi SH; Yassine HM
Antimicrob Resist Infect Control; 2018; 7():90. PubMed ID: 30069306
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and predictors of extended spectrum B-lactamase urinary tract infections among emergency department patients: A retrospective chart review.
Bou Chebl R; Assaf M; Kattouf N; Abou Arbid S; Haidar S; Geha M; Makki M; Tamim H; Abou Dagher G
Am J Emerg Med; 2021 Nov; 49():304-309. PubMed ID: 34182275
[TBL] [Abstract][Full Text] [Related]
14. Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
Abera B; Kibret M; Mulu W
PLoS One; 2016; 11(11):e0166519. PubMed ID: 27846254
[TBL] [Abstract][Full Text] [Related]
15. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
16. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study.
Stewardson AJ; Vervoort J; Adriaenssens N; Coenen S; Godycki-Cwirko M; Kowalczyk A; Huttner BD; Lammens C; Malhotra-Kumar S; Goossens H; Harbarth S; ;
Clin Microbiol Infect; 2018 Sep; 24(9):972-979. PubMed ID: 29331548
[TBL] [Abstract][Full Text] [Related]
17. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
Madhi F; Jung C; Timsit S; Levy C; Biscardi S; Lorrot M; Grimprel E; Hees L; Craiu I; Galerne A; Dubos F; Cixous E; Hentgen V; Béchet S; ; Bonacorsi S; Cohen R
PLoS One; 2018; 13(1):e0190910. PubMed ID: 29370234
[TBL] [Abstract][Full Text] [Related]
18. ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.
Pilmis B; Scemla A; Join-Lambert O; Mamzer MF; Lortholary O; Legendre C; Zahar JR
Infect Dis (Lond); 2015; 47(10):714-8. PubMed ID: 26024285
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study.
Kung CH; Ku WW; Lee CH; Fung CP; Kuo SC; Chen TL; Lee YT
J Microbiol Immunol Infect; 2015 Apr; 48(2):168-74. PubMed ID: 24064292
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
